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ABSTRACT
Background: Average life expectancy is rising,
resulting in increasing numbers of elderly, frail
individuals presenting with coronary artery disease and
requiring percutaneous coronary intervention (PCI).
PCI can be of value for this population, but little is
known about the balance of benefit versus risk,
particularly in the frail.
Objective: To determine the relationship between
frailty and clinical outcomes in patients undergoing PCI.
Methods: Patients undergoing PCI, for either stable
angina or acute coronary syndrome, were prospectively
assessed for frailty using the Canadian Study of Health
and Ageing Clinical Frailty Scale. Demographics, clinical
and angiographic data were extracted from the hospital
database. Mortality was obtained from the Office of
National Statistics.
Results: Frailty was assessed in 745 patients
undergoing PCI. The mean age of patients was 62
±12 years and 70% were males. The median frailty
score was 3 (IQR 2–4). A frailty score ≥5, indicating
significant frailty, was present in 81 (11%) patients. Frail
patients required longer hospitalisation after PCI. Frailty
was also associated with increased 30-day (HR 4.8,
95% CI 1.4 to 16.3, p=0.013) and 1 year mortality (HR
5.9, 95% CI 2.5 to 13.8, p<0.001). Frailty was a
predictor of length of hospital stay and mortality,
independent of age, gender and comorbidities.
Conclusions: A simple assessment of frailty can help
predict mortality and the length of hospital stay, and
may therefore guide healthcare providers to plan PCI
and appropriate resources for frail patients.
INTRODUCTION
Patients with symptomatic, signiﬁcant or
unstable coronary artery disease usually
require coronary revascularisation, either
with percutaneous coronary intervention
(PCI) or coronary artery bypass grafting
(CABG).1 2 Life expectancy is rising,3 result-
ing in increasing numbers of elderly people
presenting with coronary artery disease.4
Clinical decision-making for this elderly
population is challenging because little is
known about what treatment choices will
beneﬁt them, because older patients are
often excluded from clinical trials and
usually have multiple comorbidities.5–7
Traditionally, a conservative approach is
adopted for many elderly patients, yet this
cohort often has high-risk disease and might
beneﬁt the most from intervention.8–10 The
association between age and mortality
reduces signiﬁcantly when corrected for
other biological factors, such as comorbidity,
cognition, social and functional status, which
suggests that other factors, distinct from age,
are relevant.5
Frailty assessment has emerged as a
measure of biological age and it may help
predict adverse events in elderly population.
Frail patients represent a high-risk
KEY QUESTIONS
What is already known about this subject?
▸ Frailty has emerged as a marker of biological
age and it may help predict adverse events in
elderly population.
▸ Frailty has been shown to predict postoperative
complication and to correlate with quality of life,
hospital admissions and mortality, independent
of age, gender and comorbidities.
What does this study add?
▸ This study highlights the association of
Canadian Study of Health and Aging Clinical
Frailty Scale with length of hospital stay, 30-day
mortality and 1 year mortality after percutaneous
coronary intervention. This association is inde-
pendent of age and other conventional risk
factors and comorbidities.
How might this impact on clinical practice?
▸ Canadian Study of Health and Aging Clinical
Frailty Scale is a simple and quick tool to assess
frailty. It can provide additional prognostic infor-
mation, complementing conventional risk scores
and guide healthcare providers to plan percutan-
eous coronary intervention and appropriate
resources for frail patients.
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population, and frailty is a risk factor for falls, disability,
institutionalisation and death.11 Frailty has been shown to
predict postoperative complications and mortality in
elderly patients undergoing cardiac surgery12 and to cor-
relate with quality of life, hospital admissions and mortal-
ity, independent of age, gender, and comorbidities.13–15
It has been recently shown that addition of the Fried
Frailty Index improves the discriminative ability of the
Mayo Clinic PCI score for predicting angioplasty out-
comes.16 17 However, the Fried Frailty score is not readily
measurable, especially in acute clinical situations,
because it includes grip strength measurement with a
dynamometer, a 6 min walk test and a detailed quality of
life questionnaire.
This study aimed to determine whether a simple
assessment of frailty using Canadian Study of Health
and Aging Clinical Frailty Scale18 can help predict
adverse outcome after PCI, including mortality and
length of stay in hospital.
METHODS
This prospective study consisted of unselected patients
undergoing PCI at the South Yorkshire Cardiothoracic
Centre in Shefﬁeld, UK. Shefﬁeld is a tertiary centre
providing the revascularisation facilities for a catchment
population of 1.8M people in the north of England.
Patients undergoing PCI between March 2012 and
March 2014 for stable angina or acute coronary syn-
drome were eligible for the study providing a frailty
assessment was completed at the time of their PCI pro-
cedure. Patients admitted more than once during the
study period were not double counted and only data
from the ﬁrst admission were used for analyses.
Data collection and outcomes
At the time of PCI, clinical information, including
patient demographics, comorbidities and procedural
details, were collected. Our centre routinely uses the
New York PCI risk score for patients undergoing PCI
and this score was calculated for each patient. The
New York PCI risk score comprises nine variables: age,
gender, haemodynamic state, ejection fraction, timing of
myocardial infarction (MI), peripheral vascular disease,
congestive heart failure, renal failure and left main stem
stenosis19 and has been demonstrated to predict the risk
of in-hospital death following PCI.19 Frailty was assessed
Figure 1 Canadian Study of Health and Aging Clinical Frailty Scale. Adapted from Rockwood et al.18
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using the Canadian Study of Health and Aging Clinical
Frailty Scale.18 These data were collected as a service
improvement project with institutional approval. It is a
descriptive frailty scale ranging from one (very ﬁt) to
nine (terminally ill) (ﬁgure 1). This scale is quick and
easy to implement, requiring simple questions to be
asked to the patient to establish their level of frailty
according to the descriptions associated with each
category.
Study outcomes were length of hospital stay and mor-
tality at 30-day and 1 year. Mortality data are routinely
collected at the Ofﬁce of National Statistics, UK.
Statistical analysis
Data are presented as mean±SD for continuous variables
and counts or proportions for categorical variables. Data
were analysed using Student t test for continuous vari-
ables and χ2 or the Fisher’s exact test for categorical vari-
ables. Baseline clinical and procedural covariates with a
signiﬁcant trend (p<0.1) in the univariate analyses were
considered candidate variables for multivariate model.
Multivariate Cox regression analysis was used to identify
the variables independently associated with outcomes. A
two tailed p value <0.05 was used for statistical signiﬁ-
cance. All analyses were carried out using SPSS V.21
(IBM SPSS Inc, New York, USA).
RESULTS
A total of 745 patients were investigated, with a mean
age of 62±12 years, of which 70% (n=522) were male.
The mean frailty score was 3.0±1.3 (median 3, IQR 2–4)
and no patients had a frailty score higher than 7. The
scale identiﬁed 81 (11%) patients with a score of 5–9.
These were henceforth designated ‘frail’, versus patients
with a score 0–4 ‘not frail’.
Baseline variables and frailty
Baseline variables are outlined in table 1. Frail patients
were older, more likely to be female, and to have
comorbid conditions, including lower left ventricular
ejection fraction, peripheral vascular disease, a history of
congestive heart failure, renal impairment, diabetes
Table 1 Patient characteristics in over-all population and according to frailty status
Over-all population Frailty status
(n=746) Non-frail (n=665) Frail (n=81) P value
Age (years) 62.2±12.0 61.1±11.5 71.2±12.2 <0.001
Female (%) 29.9 27.2 51.9 <0.001
Height (m) 1.7±0.1 1.7±0.1 1.7±0.1 0.222
Weight (kg) 81.7±16.2 82.3±15.5 76.7±20.1 0.006
Risk factor and comorbidities
NY risk of mortality 2.2±6.7 1.6±4.2 7.4±15.6 <0.001
Hypertension (%) 39.5 37 60 <0.001
Diabetes mellitus, % 14.6 13.1 26.6 0.002
Dyslipidaemia, % 41 41.9 48.8 0.09
Peripheral vascular disease, % 7.4 6.6 13.6 0.015
Previous TIA/stroke, % 2.6 2% 7.5 0.003
Chronic renal failure, % 1.3 0.9 4.9 0.006
Chronic heart failure, % 2.1 1.7 6.2 0.011
Clinical and laboratory data
STEMI, % 39.6 39.3 41.8 0.263
Emergency PCI, % 44.2 43.7 48.75 0.335
Haemodynamic instability, % 11 9.8 21 0.002
Cardiogenic shock, % 0.5 0.4 1.6 0.188
Severe LV impairment, % 3.2 2.6 8.6 0.003
3 vessels disease, % 11.5 10.4 21 0.005
LMS disease, % 5.5 4.7 12.3 0.003
LMS, left main stem; LV, left ventricle; PCI, percutaneous coronary intervention; NY, New York; STEMI, ST segment elevation myocardial
infarction; TIA, transient ischaemic attack.
Figure 2 Frailty and length of hospital stay. Frailty was
associated with increased length of hospital stay.
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mellitus, hypertension and previous stroke. The overall
predicted mortality risk from New York PCI risk score
was 2.2±6.7%. Frail patients had substantially higher pre-
dicted mortality risk from New York PCI risk score than
non-frail patients (7.4±15.6 vs 1.6±4.2%, p<0.001).
Length of hospital stay
The total length of hospital stay was documented in 576
(77.3%) of the patients (the missing data being due to
interhospital transfer). The mean length of stay in hos-
pital was 4.9±5 days (range 1–37 days). The time interval
from admission to PCI was longer for frail patients (2.9
±5.6 vs 1.7±3.1 days, p<0.001). After PCI, frail patients
remained in hospital substantially longer than non-frail
patients (14.1±26.7 vs 3.5±8.8 days, p<0.001; ﬁgure 2).
Frailty was an independent predictor of the length of
hospital stay in multivariate regression analysis
(p<0.001).
Mortality
The 30-day mortality rate after PCI was available for 744
(99.8%) of the patients, and it was 1.5% (n=11) for the
entire group. For frail patients 30-day mortality was 4.9%
versus 1.1% for non-frail patients. Frail patients were
nearly ﬁve times more likely to die within 30 days after
PCI, compared with non-frail patients (HR 4.8, 95% CI
1.4 to 16.3, p=0.01; ﬁgure 3). Patients with higher frailty
scores had higher 30-day and 1 year mortality (table 2).
Covariates with a signiﬁcant trend (p<0.1) in the univari-
ate analyses were included in a multivariate model.
Frailty, but not age, predicted 30-day mortality. The pre-
dictors of mortality from cox-regression analyses are
shown in table 3.
The 1 year mortality rate was 2.7% for the entire
cohort; 11.1% for frail patients and 1.9% for non-frail
patients. Frailty conferred a sixfold risk of death at
1 year compared with non-frailty (HR 5.9, 95% CI 2.5 to
13.8, p<0.001; ﬁgure 3). At multivariate analysis, both
age and frailty were independent risk factors for 1 year
mortality (table 3).
DISCUSSION
Our study highlights a strong association between frailty
and length of hospital stay, 30-day mortality and 1 year
mortality after PCI. This association is independent
of age and other conventional risk factors and
comorbidities.
Risk stratiﬁcation is important in clinical decision-
making and also aids patient counselling and informed
consent.20 All PCI risk scores have age as an integral
factor.20–22 However, chronological age correlates poorly
with biological age;14 about one-third of people above
85 years may be frail, while other two-thirds are not,11
representing the heterogeneity of ageing. Exploration
into factors such as frailty, comorbidity, cognitive impair-
ment and disability are required to reorganise care and
management of elderly patients with coronary artery
disease.4–7 Although there is overlap with comorbidity
and disability, frailty is now considered to be a distinct
pathophysiological condition.5 11 The traditional cardiac
risk scores, while they offer good correlation with cardio-
vascular outcomes, may not help to identify patients who
Figure 3 Mortality according to Frailty score. Frailty was associated with higher 30-day (A) and 1-year (B) mortality.
Table 2 Frailty scores and mortality
Frailty score Mortality at 30 days Mortality at 1 year
1 0/75 (0%) 0/75 (0%)
2 2/213 (1%) 4/213 (2%)
3 2/207 (1%) 4/207 (2%)
4 3/169 (2%) 5/169 (3%)
5 2/48 (4%) 5/48 (10%)
6 1/27 (4%) 2/27 (7%)
7 1/6 (17%) 2/6 (33%)
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may beneﬁt from an invasive treatment and who should
receive conservative medical or palliative care. Novel hol-
istic tools may be required.23 The ‘Gold Standards
Framework Prognostic Indicator Guide’ (GSF), origin-
ally developed for patients with cancer, has been
recently shown to have a good accuracy to stratify risk in
patients presenting with ACS.24 25 We have shown that
frailty is an independent and perhaps more important
risk factor than age. NY risk score has age, comorbidities
and angiographic data on left main stem disease and
may therefore not help to guide which patients should
go invasive or conservative therapy. Furthermore, it
remains to be seen if replacing age with frailty in the NY
score improves its prognostic utility.
The Canadian Study of Health and Aging Clinical
Frailty Scale is a simple tool to quickly establish level of
frailty and can be used by any healthcare professional
with no extra investigations or expertise required to
complete the assessment.26 Using this scale, we found
that a sizeable proportion of patients undergoing PCI
were frail. Several clinical characteristics, including age
and comorbidities, were associated with frailty. It is
unsurprising that age is strongly associated with frailty as
people tend to become frail as they age. Frailty is consid-
ered to be a ‘geriatric’ syndrome as a broad generalisa-
tion5 11 27 although the two are not necessarily
synonymous. The relationship between frailty and being
female is in keeping with previous ﬁndings.18 27 28 This
may be due to diseases, such as osteoporosis, that are
more common in women than men; or to the later pres-
entation of coronary artery disease in women.
Osteoporosis escalates the frailty stereotype particularly
in reducing mobility. Cardiovascular risk factors and
comorbidities tend to increase with age, which may
explain their association with frailty.
Our data indicate that frailty is a risk factor for longer
hospital stay and mortality after PCI. Frailty has previ-
ously been found to be associated with longer hospital
stay29 and also with increased rates of hospitalisation for
any cause.30 Greater length of stay implies that the frail
patients are in worse health, take longer to recover after
PCI and may have more postprocedural complications.
This suggests they are at increased risk of adverse
outcomes. Greater length of stay also has implications
for increased costs of healthcare. Frailty was found to be
signiﬁcantly associated with 30-day and 1 year mortality
following PCI, suggesting that it could be considered as
short and mid-term prognostic marker. There were no
patients with frailty score 8 or 9 undergoing PCI, sug-
gesting that clinicians were managing these patients con-
servatively. Further studies are needed to ﬁnd how to
best use frailty scores in decision-making for conservative
versus invasive management.
Limitations
This study has several limitations. It was not logistically
possible to enrol all consecutive patients, especially out
of hours, which may have excluded high-risk emergency
patients. Furthermore, only patients undergoing PCI
were included in this study and it is likely that a propor-
tion of frail patients were not offered interventions
based on clinical judgment about futility of invasive
approach in these patients. While mortality rates were
available for almost all patients, total length of hospital
stay was not available for 22.7% patients as many patients
were repatriated to their local hospitals after PCI.
Finally, the Canadian Study of Health and Aging Clinical
Frailty Scale used to assess frailty is subjective in nature
and therefore predisposed to interobserver variability.
However, this does not appear to reduce the predictive
power of this frailty score to predict outcomes.
CONCLUSION
The Canadian Study of Health and Aging Clinical Frailty
Scale can help to predict mortality and the length of
hospital stay after PCI. This simple and quick to use
assessment tool can provide additional prognostic infor-
mation, complementing conventional risk scores and
guide healthcare providers to plan PCI and appropriate
resources for frail patients.
Acknowledgements The authors are grateful to all the interventional
cardiologists at South Yorkshire Cardiothoracic Centre who contributed to this
study. The authors would also like to thank Louisa Yates for help in data
extraction.
Table 3 Predictors of mortality from cox regression analyses
Variable 30-Day mortality 1 Year mortality
HR 95% CI p Value HR 95% CI p Value
Frailty 1.8 1.1 to 3.7 0.05 1.9 1.6 to 5.3 0.03
Age (per 10 year) 1.0 0.9 to 1.1 0.78 1.3 1.1 to 1.9 0.04
Haemodynamic instability 6.6 1.5 to 30.0 0.01 2.9 1.1 to 7.7 0.04
Chronic heart failure 7.2 1.0 to 50.2 0.05 5.2 1.6 to 16.4 0.01
Renal failure 17.6 2.4 to 130 0.01 4.2 1.0 to 16.8 0.10
Diabetes mellitus 1.8 0.4 to 8.5 0.45 1.9 0.8 to 5.1 0.08
COPD 7.0 0.7 to 60.5 0.09 2.4 0.3 to 21.2 0.44
TIA/stroke 2.2 0.3 to 20.0 0.47 2.3 0.6 to 8.7 0.09
Significant variables are shown as bold.
COPD, chronic obstructive pulmonary disease; TIA, transient ischaemic stroke.
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